المؤلفون: Andrea Gruber (Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna), Martin Czejka (Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna), Philipp Buchner (Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna), Marie Kitzmueller (Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna), Nairi Kirchbaumer Baroian (Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna), Christian Dittrich (Applied Cancer Research - Institution for Translational Research Vienna (ACR-ITR VIEnna)), Azra Sahmanovic Hrgovcic (Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna)

المصدر: Cancer Chemotherapy and Pharmacology

مصطلحات موضوعية: Erlotinib, Long-time administration, Therapeutic drug monitoring, Interaction assessment, PBPK model

وصف الملف: application/pdf

Relation: isPartOf:https://phaidra.univie.ac.at/o:243553[u:scholar collection]; hdl:11353/10.937686; https://phaidra.univie.ac.at/o:937686

الاتاحة: https://doi.org/10.1007/s00280-018-3545-4
https://phaidra.univie.ac.at/o:937686